Circulating immune markers predict the therapeutic effect in primary lung cancer.

03 medical and health sciences 0302 clinical medicine 3. Good health
DOI: 10.1200/jco.2021.39.15_suppl.e21203 Publication Date: 2021-06-02T15:06:20Z
ABSTRACT
e21203 Background: Radiotherapy (RT), surgical resection (SR), and immunotherapy (IT) as main therapies in lung cancer have either suppressive or stimulatory effects on the immune system. It’s still unclear mechanism involved systemic changes of cells blood. Peripheral blood lymphocyte subpopulations were useful markers for evaluating response tumor patients. Hence, we aimed to systematically investigate alteration during local evaluate antitumor treatment effects. Methods: Blood samples obtained EDTA coated tubes then centrifuged gently white cell separation. The 10% DMSO 90% FBS frozen slowly -80°C refrigerator. following fluorochrome-conjugated surface nuclear antibodies used subtyping: CD11b, CD45, CD19, CD3, CD56, CD4, CD8a, CD25,CD127 FOXP3. staining detected BD FACS machine data analyzed by paired T-test. percentage Lymphocytes, Myeloid cells, B T Treg, CD8+ CD4+ NK NKT examined. Results: Between July 2019 January 2020, a total 176 patients eligible, including 135 RT 29 SR patients,12 IT patients, with both collection Pre, During End therapies. Before therapies, group was significantly higher than (RT v.s mean:64.1 55.3, P = 0.02) while mean:28.2 34.5, 0.04)and Tregs mean:0.0 0.1, 0.055) lower. baseline level their subtypes showed significant difference these two After myeloid lymphocytes, different. There is no due smaller number In group, lymphocytes (Pre-RT End-RT mean:75.2 54.3, 0.004) mean:12.6 8.0, 0.03) decreased other didn’t show any after RT. Interestingly, there increase (mean:59.0 62.1, p trend reduction (mean:34.5 32.0, SR. addition, an increased IT. Conclusions: are some different patterns distribution leukocytes operable inoperable between All RT, changed peripheral subpopulations. Further validation study warranted validate our findings particularly circulating marker status SR, IT, well relationship microenvironment implication personalized care.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....